IB-MECA structure
|
Common Name | IB-MECA | ||
---|---|---|---|---|
CAS Number | 152918-18-8 | Molecular Weight | 510.286 | |
Density | 2.0±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C18H19IN6O4 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | N/A |
Use of IB-MECAPiclidenoson (IB-MECA) is an agonist of the adenosine A3 receptor with EC50 values of 0.11 μM. IC50 value: 0.11 μM (EC50) [3]Target: adenosine A3 receptorin vitro: Piclidenoson has been shown to play important roles in cell proliferation and apoptosis in a variety of cancer cell lines. ThePiclidenoson was capable of decreasing intracellular cyclic adenosine monophosphate (cAMP) that was the reason for the presence of functional A3 adenosine receptor on the cell lines. Piclidenoson significantly reduced cell viability in a dose-dependent manner. Piclidenoson, an A3AR agonist, inhibits the growth of different cancer cell types like melanoma, colon, breast, leukemia, and prostatePiclidenoson was able to inhibit forskolin-stimulated cAMP levels with an EC50 value of 0.82 μM in OVCAR-3 cells. Piclidenoson was able to inhibit forskolin-stimulated cAMP levels with an EC50 value of 1.2 μM in Caov-4 cells.in vivo: Administrations of single intraperitoneal doses of either Piclidenoson 0.5 h post-irradiation resulted in statistically significant increases of MST in comparison with the control irradiated mice.[2] |
Name | (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-2-carboxamide |
---|---|
Synonym | More Synonyms |
Description | Piclidenoson (IB-MECA) is an agonist of the adenosine A3 receptor with EC50 values of 0.11 μM. IC50 value: 0.11 μM (EC50) [3]Target: adenosine A3 receptorin vitro: Piclidenoson has been shown to play important roles in cell proliferation and apoptosis in a variety of cancer cell lines. ThePiclidenoson was capable of decreasing intracellular cyclic adenosine monophosphate (cAMP) that was the reason for the presence of functional A3 adenosine receptor on the cell lines. Piclidenoson significantly reduced cell viability in a dose-dependent manner. Piclidenoson, an A3AR agonist, inhibits the growth of different cancer cell types like melanoma, colon, breast, leukemia, and prostatePiclidenoson was able to inhibit forskolin-stimulated cAMP levels with an EC50 value of 0.82 μM in OVCAR-3 cells. Piclidenoson was able to inhibit forskolin-stimulated cAMP levels with an EC50 value of 1.2 μM in Caov-4 cells.in vivo: Administrations of single intraperitoneal doses of either Piclidenoson 0.5 h post-irradiation resulted in statistically significant increases of MST in comparison with the control irradiated mice.[2] |
---|---|
Related Catalog | |
References |
Density | 2.0±0.1 g/cm3 |
---|---|
Molecular Formula | C18H19IN6O4 |
Molecular Weight | 510.286 |
Exact Mass | 510.051239 |
PSA | 134.42000 |
LogP | 2.08 |
Index of Refraction | 1.808 |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
RIDADR | NONH for all modes of transport |
HS Code | 2934999090 |
~% IB-MECA CAS#:152918-18-8 |
Literature: Journal of Medicinal Chemistry, , vol. 37, # 5 p. 636 - 646 |
~% IB-MECA CAS#:152918-18-8 |
Literature: Journal of Medicinal Chemistry, , vol. 37, # 5 p. 636 - 646 |
~% IB-MECA CAS#:152918-18-8 |
Literature: Journal of Medicinal Chemistry, , vol. 37, # 5 p. 636 - 646 |
~% IB-MECA CAS#:152918-18-8 |
Literature: Journal of Heterocyclic Chemistry, , vol. 37, # 2 p. 339 - 341 |
~% IB-MECA CAS#:152918-18-8 |
Literature: Journal of Heterocyclic Chemistry, , vol. 37, # 2 p. 339 - 341 |
~% IB-MECA CAS#:152918-18-8 |
Literature: Journal of Medicinal Chemistry, , vol. 37, # 5 p. 636 - 646 |
HS Code | 2934999090 |
---|---|
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Equilibrium and kinetic selectivity profiling on the human adenosine receptors.
Biochem. Pharmacol. 105 , 34-41, (2016) Classical evaluation of target selectivity is usually undertaken by measuring the binding affinity of lead compounds against a number of potential targets under equilibrium conditions, without conside... |
|
Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.
J. Thorac. Cardiovasc. Surg. 140(2) , 440-6, (2010) Adenosine and the activation of specific adenosine receptors are implicated in the attenuation of inflammation and organ ischemia-reperfusion injury. We hypothesized that activation of A(1), A(2A), or... |
|
Activation of adenosine low-affinity A3 receptors inhibits the enteric short interplexus neural circuit triggered by histamine.
Am. J. Physiol. Gastrointest. Liver Physiol. 297(6) , G1147-62, (2009) We tested the novel hypothesis that endogenous adenosine (eADO) activates low-affinity A3 receptors in a model of neurogenic diarrhea in the guinea pig colon. Dimaprit activation of H2 receptors was u... |
UNII-30679UMI0N |
Piclidenoson |
(2S,3S,4R,5R)-3,4-Dihydroxy-5-{6-[(3-iodobenzyl)amino]-9H-purin-9-yl}-N-methyltetrahydro-2-furancarboxamide |
IBMECA |
(2S,3S,4R,5R)-3,4-Dihydroxy-5-{6-[(3-iodobenzyl)amino]-9H-purin-9-yl}-N-methyltetrahydrofuran-2-carboxamide (non-preferred name) |
CF 101 |
3-IB-Meca |
IB-MECA |
CF101 |